IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appli	cation of:)	
MARKKU	ANTTILA	:)	Examiner: Shirley V. Gembeh
Application	ı No.: 10/777,211	;	Group Art Unit: 1614
Filed: Febr	uary 13, 2004)	
TI	ETHOD FOR ENHANCING HE BIOAVAILABILITY OF SPEMIFENE	;) ;)	March 16, 2007

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

<u>INFORMATION DISCLOSURE STATEMENT</u>

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.

It is respectfully requested that the above information be considered by the

Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such

information has been considered.

We also enclose a check for the required fee of \$180.00 to cover the

Information Disclosure Statement under 37 C.F.R. 1.97(c)(2).

Applicants' undersigned attorney may be reached in our New York office by

telephone at (212) 218-2100. All correspondence should continue to be directed to our

address given below.

Respectfully submitted,

Raymond R. Mandra Attorney for Applicants Registration No.: 34,382

FITZPATRICK, CELLA, HARPER & SCINTO

30 Rockefeller Plaza

New York, New York 10112-3800

Facsimile: (212) 218-2200

FORM PTO 1449 (n	nodified) S. DEPARTMENT OF COM	MEDCE	ATTY DOCKET NO. 03426.000150.	APPLICA	TION NO. 10/777,2	<u> </u>
PA LIST OF I	TENT AND TRADEMARK REFERENCES CITED BY A (Use several sheets if neces	OFFICE APPLICANT(S)	APPLICANT MARKKU A	NTTILA	l	
	(000 001010101000011110000		FILING DATE February 13, 2004		GROUP 17	761
			U.S. PATENT DOCUMENTS			
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

		FC	PREIGN PATENT DOCUMENTS			
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
) (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Malcolm Row Williams & W	vland, et al., "Clin /ilking, 1995, pp. '	ical Pharmacokinetics, Concepts a 120-121	nd Appl	ications", 3	rd Edition,
	FDA Guidano	e For Industry Fo	ood, Effect Bioavailability and Fed E	Bioequiv	alence Stu	dies, 2002
	Christopher & S	J. H. Porter, et al. ignal Transduction	, Lipid Based Formulations for Oral on Research, 21(2&3), 215-257 (200	Admini 1), pp. 2	stration, J. 15-257	of
EXAMINER			DATE CONSIDERED			

|--|

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.